Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma

Inclusion Criteria:

* Histologically confirmed indolent B-cell non-Hodgkin lymphoma.
* Radiological measurable disease.
* Previous treatment for lymphoma is allowed, with the exception of use of bendamustine within 6 months or any prior use of vincristine sulfate liposome injection
* Eastern Cooperative Oncology Group performance status 0 or 1;
* Life expectancy of at least 6 months;
* Adequate organ and marrow function;
* Women of child-bearing potential and men must agree to use adequate contraception.
* Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* History of allergic reactions attributed to any drug used in the study.
* Any lymphoma-directed therapy within 4 weeks.
* Any prior treatment with vincristine sulfate liposome injection.
* Prior treatment with bendamustine or vincristine sulfate within 180 days of enrollment.
* Patients who are receiving any other investigational agents with the exception of endocrine therapy for breast or prostate cancer.
* Central nervous system involvement.
* Peripheral sensory or motor neuropathy.
* History of a demyelinating condition.
* Positive test for the Human Anti-Chimeric Antibody (HACA).
* Patients receiving any medications or substances that are strong inhibitors or inducers of Cytochrome P450, family 3, subfamily A (CYP3A) enzyme are ineligible.
* Uncontrolled intercurrent illness.
* Prisoners.
* Pregnant or breast-feeding women.
* Known Human Immunodeficiency Virus (HIV) or active Hepatitis B infection
* Any prior or active cancer, which in the opinion of the investigator would preclude safe participation in this study.